Tonix Pharmaceuticals Holding Corp. (TNXP)

A new treatment option for fibromyalgia, a chronic pain disorder affecting over 10 million adults in the United States, has recently received approval and is offering a different approach to managing the condition. TONMYA™, developed by Tonix Pharmaceuticals Holding Corp., was approved by the FDA on August 15, 2025, and represents the first new prescription medicine for fibromyalgia in more than 15 years.

A Novel Approach to Fibromyalgia Pain

Data presented at the 2026 Non-Opioid Pain Therapeutics Summit in Boston, Massachusetts, on January 29, 2026, demonstrated that TONMYA™ significantly reduced fibromyalgia pain compared to a placebo in the Phase 3 RESILIENT study. The treatment, previously investigated as TNX-102 SL, utilizes a unique sublingual formulation – meaning it’s absorbed under the tongue – designed for bedtime dosing. This method is intended to bypass first-pass metabolism, optimizing the amount of the active drug available during sleep and minimizing exposure to a persistent metabolite.

Did You Know? TONMYA is the first new prescription medicine approved by the FDA for fibromyalgia in over 15 years.

According to Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, TONMYA’s role is as a centrally-acting, differentiated non-opioid treatment. He highlighted the need for alternatives to opioids, which are frequently prescribed off-label for fibromyalgia, but carry risks and potential side effects.

How TONMYA Works

Dr. Gregory Sullivan, Chief Medical Officer of Tonix Pharmaceuticals, explained that the sublingual formulation largely avoids initial metabolism in the liver, reducing the formation of norcyclobenzaprine, a metabolite believed to interfere with the treatment’s duration. This results in a different pharmacokinetic profile compared to traditional oral cyclobenzaprine, with greater availability of the parent drug during sleep and reduced exposure to the active metabolite during the day. The bedtime administration is also designed to address the non-restorative sleep often experienced by fibromyalgia patients.

Expert Insight: The focus on optimizing drug exposure during sleep suggests a targeted approach to addressing a core symptom of fibromyalgia – sleep disturbance – and potentially improving overall symptom management with a potentially more favorable side effect profile.

TONMYA is indicated for the treatment of fibromyalgia in adults. Tonix Pharmaceuticals also markets treatments for acute migraine, Zembrace^® SymTouch^® and Tosymra^®. The company’s development pipeline includes candidates for a range of conditions, including acute stress reaction, major depressive disorder, organ transplant rejection, and infectious diseases.

Looking Ahead

While TONMYA has received FDA approval, further research and clinical experience will be crucial to fully understand its long-term effects and optimal use. Tonix Pharmaceuticals is continuing to investigate TNX-102 SL for other conditions, including acute stress reaction and acute stress disorder, in collaboration with the University of North Carolina and with funding from the U.S. Department of Defense. It is possible that, with continued study, TONMYA could become a cornerstone of fibromyalgia treatment plans, offering a non-opioid option for those seeking relief. Analysts expect ongoing monitoring of TONMYA’s impact on patient outcomes and potential for broader application within the field of pain management.

Frequently Asked Questions

What is fibromyalgia?

Fibromyalgia is a chronic pain disorder affecting more than 10 million adults in the U.S.

How is TONMYA administered?

TONMYA is a sublingual formulation, meaning it is absorbed under the tongue, and is designed for bedtime dosing.

Are there any contraindications for using TONMYA?

TONMYA is contraindicated in patients with hypersensitivity to cyclobenzaprine, those using MAO inhibitors, during the acute recovery phase of myocardial infarction, and in patients with certain heart or thyroid conditions.

As new treatments like TONMYA emerge, how might the landscape of chronic pain management evolve to better address the complex needs of patients?